ArticleScientific reports2025
Green HPLC technique development for the simultaneous determination of the potential combination of Mirabegron and Tamsulosin.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Targeted Determination of Residual Sex Hormones in Cosmetics Using Magnetic Solid-Phase Extraction with Isotope-Labeled Internal Standards by UHPLC-MS/MS.Molecules (Basel, Switzerland) · 2025Article
- Supramolecular Solvent-Based Extraction of Bisphenols and Alkylphenols in Botanical Dietary Supplements Prior to HPLC-MS/MS Analysis.Foods (Basel, Switzerland) · 2025Article
- Development and validation of a green/blue UHPLC-MS/MS method for trace pharmaceutical monitoring.Scientific reports · 2025Article
- Eco-friendly spectrophotometric quantification of the potential combination of mirabegron and tamsulosin.Scientific reports · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mirabegron and tamsulosin have recently been prescribed to men with overactive bladder for the treatment of benign prostatic hypertrophy. An efficient and environmentally friendly HPLC method was developed to accurately measure the levels of mirabegron and tamsulosin in both their pure form and in medication formulations. Full separation was achieved on an X-Bridge C18 column using a gradient elution of (The A mobile phase was a buffer solution containing 1 mL of trifluoroacetic acid and 3 mL of triethylamine in 1,000 milliliters of water, the pH of the solution was then adjusted to 3 using triethylamine and the B-mobile phase was acetonitrile). The chromatographic peaks were obtained at a wavelength of 220 nm. Mirabegron and tamsulosin were identified with retention time values of 2.4 min and 8.9 min, respectively. In the concentration ranges of 2.5-55 µg/mL for mirabegron and 5-110 µg/mL for tamsulosin, remarkable linearity was seen. The limits of detection for the two analytes were 0.28 and 0.55 µg/mL, respectively, and their R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.